Fig. 1.
GATA-3 is expressed by ILC2s and is required for ILC2 development in vivo. (A) Gating strategy for analysis of BM and lung ILC2s. Histograms show intracellular expression of GATA-3 of ILC2s (bold line) compared with CD3+ CD4+ T cells (black line) and CD19+ B lymphocytes (gray area). Numbers indicate relative frequencies of gated populations. Shown are representative results from three independent experiments (n ≥ 6 total mice analyzed). (B and C) Analysis of lymphocytes from BM (B) and lung (C) of Rag2−/−Il2rg−/− hosts transplanted with Gata3+/+ and Gata3−/− precursors for expression of the indicated surface markers. Plots show gating strategy for ILC2s. Bar graphs show quantification of the indicated donor-derived populations in chimeras. (D) Analysis of pulmonary Lin− lymphocytes for CD127 and intracellular IL-5 expression. Plots show gating strategy for IL-5+ lymphocytes and ILC2s. Bar graphs show quantification of the indicated populations in Gata3+/+ and Gata3−/− chimeras. (B–D) Shown are representative results from two independent experiments with n = 3 (Gata3+/+) or 5 (Gata3−/−) total mice analyzed per genotype. ns, not significant. *P < 0.05; ***P < 0.001.